| Literature DB >> 29269607 |
Tsuyoshi Yamamoto1, Hirofumi Nakano1, Kazuro Shiomi1,2, Kiyofumi Wanibuchi3, Hisashi Masui3, Takashi Takahashi3, Yasuteru Urano4,5, Tohru Kamata6.
Abstract
Reactive oxygen species (ROS) generated by reduced nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (Nox)1 mediate cellular signalings involved in normal physiological processes, and aberrant control of Nox1 has been implicated in the pathogenesis of various diseases. Therefore, Nox1 could have great potential as a therapeutic target. Here, we identified a novel Nox1 inhibitor, NOS31 secreted from Stretomyces sp. and analyzed its chemical structure. Furthermore, NOS31 was found to selectively inhibit Nox1-mediated ROS generation, with only a marginal effect on other Nox isoforms (Nox2-5) and no ROS scavenging activity. This compound blocked both Nox organizer 1 (NOXO1)/Nox activator 1 (NOXA1)-dependent and phorbol 12-myristate 13-acetate-stimulated Nox1-mediated ROS production in colon cancer cells. NOS31 inhibited the proliferation of several colon carcinoma and gastric cancer cell lines that upregulate the Nox1 system, whereas it had no appreciable effect on normal cells with low levels of Nox1. The finding suggests that NOS31 is a unique, potent Nox1 inhibitor of microbial origin and raises its possibility as a therapeutic agent for inhibiting gastrointestinal cancer cell growth.Entities:
Keywords: NADPH oxidase inhibitor; NOS31; gastrointestinal cancer cell; reactive oxygen species; reduced nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (Nox)1
Mesh:
Substances:
Year: 2017 PMID: 29269607 DOI: 10.1248/bpb.b17-00804
Source DB: PubMed Journal: Biol Pharm Bull ISSN: 0918-6158 Impact factor: 2.233